Welcome to our dedicated page for Senseonics SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Senseonics Holdings, Inc. (SENS) provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Senseonics is a medical technology company focused on the development and manufacturing of long-term implantable continuous glucose monitoring (CGM) systems, and its filings offer detailed insight into its financial condition, capital structure, and corporate actions.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, and financial statements related to its Eversense 365 and Eversense E3 glucose monitoring products. Form 8-K current reports disclose material events, such as preliminary financial results, the implementation of a 1-for-20 reverse stock split, special stockholder meetings, and updates on commercialization plans and collaborations.
Investors can also review proxy materials, such as the DEF 14A definitive proxy statement for the special meeting of stockholders that authorized the reverse stock split and proportional reduction in authorized shares. In addition, a Form 25 filing documents the voluntary removal of Senseonics’ common stock from listing and registration on the NYSE American in connection with the transfer of its listing to the Nasdaq Global Select Market.
Through this page, users can follow how Senseonics reports on topics such as revenue updates, capital structure changes, and governance matters. Real-time updates from EDGAR ensure that new filings, including Forms 8-K, 10-Q, and 10-K, appear as they are submitted. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections, and clarify technical language, making it easier to understand how Senseonics’ regulatory disclosures relate to its long-term implantable CGM business.
For those researching SENS, this filings page serves as a central location to review the company’s official SEC documents, track its corporate history, and analyze how its medical technology operations and public company obligations intersect.
Senseonics Holdings, Inc. is soliciting proxies for its virtual 2026 Annual Meeting on May 20, 2026 to elect three Class I directors, seek advisory votes on executive compensation and frequency, ratify KPMG as auditor, approve doubling authorized common stock to 140,000,000 shares, and approve a new 2026 Equity Incentive Plan.
The record date is March 26, 2026, with 41,795,466 shares outstanding on that date. The proxy explains voting mechanics, vote thresholds, broker voting treatment (Proposals 1,2,3,6 are non-routine), and discloses reserved shares and recent financial context including $15.8M gross profit for the twelve months ended December 31, 2025 and an accumulated deficit of $1 billion.
Senseonics Holdings, Inc. is holding a virtual 2026 Annual Meeting on May 20, 2026 to vote on six key proposals. Stockholders will elect three directors, cast advisory votes on executive pay and its frequency, and ratify KPMG LLP as auditor for 2026.
The company is asking investors to approve an amendment to double authorized common stock from 70,000,000 to 140,000,000 shares and to approve a new 2026 Equity Incentive Plan. Common shares outstanding were 41,795,466 as of March 26, 2026, with 14,233,357 additional shares reserved for incentives and warrants.
ROEDER DOUGLAS A reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings director Douglas A. Roeder received 2,218 shares of common stock as a grant in lieu of cash board fees. The shares were valued at $6.65 each, matching the Nasdaq closing price on April 1, 2026, for a total of $14,749.70 in compensation value.
This was a compensation-related award under the company’s non-employee director compensation policy, not an open-market purchase. After this grant, Roeder directly holds 121,949 shares of Senseonics common stock.
Prince Douglas S reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. director Douglas S. Prince received 1,221 shares of common stock on April 1, 2026 as a grant. The shares were issued under the non-employee director compensation policy in lieu of quarterly retainer fees, based on $8,119.65 divided by the $6.65 closing price. Following this award, he directly holds 57,964 common shares.
Fiorentino Edward reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. reported that director Edward Fiorentino received a grant of common stock as board compensation. On April 1, 2026, he was issued 2,124 shares under the non-employee director compensation policy in lieu of a $14,124.60 quarterly cash retainer at $6.65 per share. Following this award, he directly holds 73,487 shares of Senseonics common stock.
Steven Edelman reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings director Steven Edelman received a stock grant as part of his board compensation. He was awarded 1,936 shares of common stock, valued at $12,874.40 based on a $6.65 closing price on April 1, 2026, in lieu of quarterly cash retainer fees.
Following this grant, Edelman directly holds 78,829 shares of Senseonics common stock. This was a compensation-related award rather than an open-market purchase or sale, and no derivative securities are reported in this filing.
Senseonics Holdings, Inc. is soliciting proxies for its virtual 2026 Annual Meeting to be held on May 20, 2026. The record date is March 26, 2026, when 41,795,466 shares were outstanding. Key proposals include the election of three Class I directors (Timothy T. Goodnow, Francine R. Kaufman and Sharon Larkin), an advisory say-on-pay vote and a say-on-frequency vote, ratification of KPMG LLP as independent auditors, approval to increase authorized common shares from 70,000,000 to 140,000,000, and approval of the Senseonics Holdings, Inc. 2026 Equity Incentive Plan.
The proxy discloses reserve and capitalization context as of the record date: 41,795,466 shares outstanding, aggregate reserved shares of 14,233,357 across plans and warrants, and 13,971,177 unissued, unreserved shares. The company reported $15.8 million gross profit for the twelve months ended December 31, 2025 and an accumulated deficit of $1 billion. The Board recommends a vote FOR all proposals.
Senseonics Holdings, Inc. director Douglas A. Roeder purchased additional company stock in the open market. On March 13, 2026, he bought 17,500 shares of common stock at $5.73 per share. Following this transaction, his direct ownership increased to 119,731 shares, reflecting a meaningful personal investment in the company.
Senseonics Holdings, Inc. President and CEO Timothy T. Goodnow made an open-market purchase of common stock. On March 13, 2026, he bought 17,225 shares at a weighted average price of $5.79 per share, bringing his direct ownership to 651,243 shares after the transaction.